Clinigen Group plc Director/PDMR Shareholding (8881M)

TIDMCLIN

RNS Number : 8881M

Clinigen Group plc

19 October 2016

19 October 2016

Director's Share Dealing

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services group, announces that it was notified on 18 October 2016 that the following transactions took place on 18 October 2016.

Shaun Chilton, the Group Chief Executive Officer-designate, has exercised a total of 206,389 nil cost options over ordinary shares of 0.1 pence each in the Company. The options have been satisfied by shares from the Clinigen Group Employment Benefit Trust. He has subsequently sold 97,246 ordinary shares of 0.1 pence each in the Company at a price of 750 pence per share in order to meet the expected tax obligations.

Following these transactions, Mr Chilton's total beneficial interest in the Company is 412,943 ordinary shares representing approximately 0.36 per cent of the current issued share capital.

Separately, Peter George, the Group Chief Executive Officer, sold 2,200,000 ordinary shares of 0.1 pence each in the Company at a price of 750 pence per share.

Following these transactions, Mr George's total beneficial interest in the Company is 3,357,242 ordinary shares, representing approximately 2.93 per cent of the current issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1     Details of the person discharging 
        managerial responsibilities/person 
        closely associated 
----  ------------------------------------------------------------------ 
 a)    Name                    Shaun Chilton 
----  ----------------------  ------------------------------------------ 
 2     Reason for the notification 
----  ------------------------------------------------------------------ 
 a)    Position/status         Group Chief Executive Officer-designate 
----  ----------------------  ------------------------------------------ 
 b)    Initial                 Initial Notification 
        notification 
        /Amendment 
----  ----------------------  ------------------------------------------ 
 3     Details of the issuer, emission allowance 
        market participant, auction platform, 
        auctioneer or auction monitor 
----  ------------------------------------------------------------------ 
 a)    Name                    Clinigen Group plc 
----  ----------------------  ------------------------------------------ 
 b)    Legal Entity            N/A 
        Identifier 
----  ----------------------  ------------------------------------------ 
 4     Details of the transaction(s): section 
        to be repeated for (i) each type 
        of instrument; (ii) each type of 
        transaction; (iii) each date; and 
        (iv) each place where transactions 
        have been conducted 
----  ------------------------------------------------------------------ 
 a)    Description             Ordinary shares of 0.1 pence 
        of the financial        each 
        instrument,             GB00B89J2419 
        type of 
        instrument 
        Identification 
        code 
----  ----------------------  ------------------------------------------ 
 b)    Nature of                    1. The exercise of 206,389 
        the transaction              options over ordinary shares 
                                     in the Company following 
                                     the vesting of an award 
                                     granted under the Long Term 
                                     Incentive Plan. 
                                     2. The sale of 97,246 ordinary 
                                     shares in the Company made 
                                     in order to meet expected 
                                     tax obligations arising 
                                     from the transaction described 
                                     in 1. 
----  ----------------------  ------------------------------------------ 
 c)    Currency                GBP 
----  ----------------------  ------------------------------------------ 
 d)    Price(s)                     Price(s)              Volume(s) 
        and volume(s) 
----  ----------------------  --------------------  -------------------- 
                                      750p                 97,246 
 ---------------------------  --------------------  -------------------- 
 
 e)    Aggregated               97,246 
        information 
   - Aggregated                  750p 
    volume 
   - Price                       GBP729,345 
   - Aggregated 
    total 
 ---------------------------  ------------------------------------------ 
 f)    Date of                 18 October 2016 
        the transaction 
----  ----------------------  ------------------------------------------ 
 g)    Place of                London Stock Exchange, AIM 
        the transaction 
----  ----------------------  ------------------------------------------ 
 
 
 1     Details of the person discharging 
        managerial responsibilities/person 
        closely associated 
----  -------------------------------------------------------- 
 a)    Name                    Peter George 
----  ----------------------  -------------------------------- 
 2     Reason for the notification 
----  -------------------------------------------------------- 
 a)    Position/status         Group Chief Executive Officer 
----  ----------------------  -------------------------------- 
 b)    Initial                 Initial Notification 
        notification 
        /Amendment 
----  ----------------------  -------------------------------- 
 3     Details of the issuer, emission allowance 
        market participant, auction platform, 
        auctioneer or auction monitor 
----  -------------------------------------------------------- 
 a)    Name                    Clinigen Group plc 
----  ----------------------  -------------------------------- 
 b)    Legal Entity            N/A 
        Identifier 
----  ----------------------  -------------------------------- 
 4     Details of the transaction(s): section 
        to be repeated for (i) each type 
        of instrument; (ii) each type of 
        transaction; (iii) each date; and 
        (iv) each place where transactions 
        have been conducted 
----  -------------------------------------------------------- 
 a)    Description             Ordinary shares of 0.1 pence 
        of the financial        each 
        instrument,             GB00B89J2419 
        type of 
        instrument 
        Identification 
        code 
----  ----------------------  -------------------------------- 
 b)    Nature of               Sale of shares 
        the transaction 
----  ----------------------  -------------------------------- 
 c)    Currency                GBP 
----  ----------------------  -------------------------------- 
 d)    Price(s)                   Price(s)        Volume(s) 
        and volume(s) 
----  ----------------------  ---------------  --------------- 
                                    750p          2,200,000 
 ---------------------------  ---------------  --------------- 
 
 e)    Aggregated               2,200,000 
        information 
   - Aggregated                  750p 
    volume 
   - Price                       GBP16,500,000 
   - Aggregated 
    total 
 ---------------------------  -------------------------------- 
 f)    Date of                 18 October 2016 
        the transaction 
----  ----------------------  -------------------------------- 
 g)    Place of                London Stock Exchange, AIM 
        the transaction 
----  ----------------------  -------------------------------- 
 

-Ends-

Contact Details

 
 Clinigen Group plc                     Tel: [phone] 
                                         495 010 
 Peter George, Group Chief Executive 
  Officer 
 Shaun Chilton, Group Chief 
  Executive Officer - designate 
  Martin Abell, Group Chief Financial 
  Officer 
 
 Numis Securities Limited               Tel: +44 (0) 20 
                                         7260 1000 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
  James Black / Tom Ballard 
  (Corporate Broking) 
 
 Peel Hunt LLP - Joint Broker           Tel: +44 (0) 20 
                                         7418 8900 
 James Steel / Dr Christopher 
  Golden 
 
 Instinctif Partners (media             Tel: +44 (0) 20 
  relations)                             7457 2020 
 Melanie Toyne-Sewell / Jayne 
  Crook / Emma Barlow                   Email: [e-mail] 
 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time.

The Group consists of five synergistic businesses focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.

The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).

Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital commercial products.

For more information, please visit www.clinigengroup.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHLLFIAIILTLIR

(END) Dow Jones Newswires

October 19, 2016 03:00 ET (07:00 GMT)